Evgen Pharma PLC Result of General Meeting (4820A)
December 28 2017 - 5:49AM
UK Regulatory
TIDMEVG
RNS Number : 4820A
Evgen Pharma PLC
28 December 2017
For immediate release 28 December 2017
Evgen Pharma plc
("Evgen Pharma" or "the Company")
Result of General Meeting
Evgen Pharma (AIM: EVG), a clinical stage drug development
company focused on the treatment of cancer and neurological
conditions, is pleased to announce that all resolutions were duly
passed at the General Meeting held earlier today.
The General Meeting follows the announcement on 8 December 2017
which gave details of a placing of 19,166,667 new ordinary shares
of 0.25p each ("Placing Shares") in the Company at a price of 12p
per ordinary share (the "Placing") to raise GBP2.3 million (before
expenses). The Placing is now unconditional.
Application has been made for the Placing Shares to be admitted
to trading on AIM which is expected to occur at 8.00 a.m. tomorrow,
29 December 2017.
Total Voting Rights
Following Admission the Company's issued share capital will
comprise 93,276,858 ordinary shares with voting rights. The figure
of 93,276,858 ordinary shares may therefore be used by shareholders
in the Company as the denominator for the calculations by which
they will determine if they are required to notify their interest
in, or a change in their interest in, the share capital of the
Company under the FCA's Disclosure and Transparency Rules.
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014. Market soundings, as
defined in MAR, were taken in respect of the proposed fundraise
with the result that certain persons became aware of inside
information, as permitted by MAR. That inside information is set
out in this announcement and has been disclosed as soon as possible
in accordance with paragraph 7 of article 17 of MAR. Therefore,
those persons that received inside information in a market sounding
are no longer in possession of inside information relating to the
Company and its securities.
Enquiries:
Evgen Pharma plc c/o +44 (0) 20 7466
Dr Stephen Franklin, CEO 5000
Richard Moulson, CFO
www.evgen.com
Buchanan
Mark Court, Sophie Wills, Stephanie +44 (0) 20 7466
Watson 5000
Northland Capital Partners Limited
Matthew Johnson, Gerry Beaney
(Corporate Finance)
John Howes, Rob Rees (Corporate +44 (0) 20 3861
Broking) 6625
Notes for editors:
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company whose
lead programmes are in breast cancer and subarachnoid haemorrhage,
a type of stroke. The Company's core technology is Sulforadex(R), a
method for synthesising and stabilising the naturally occurring
compound sulforaphane and novel proprietary analogues based on
sulforaphane. The lead product, SFX-01, is a patented composition
of synthetic sulforaphane and alpha-cyclodextrin.
Evgen Pharma commenced operations in January 2008 and has its
headquarters at The Colony, Wilmslow, Cheshire, and its registered
office is at the Liverpool Science Park, Liverpool. It joined the
AIM market of the London Stock Exchange in October 2015 and trades
under the ticker symbol EVG.
For further information, please visit: www.evgen.com
For commissioned research on the Company, please visit:
http://evgen.com/investors/analyst-coverage/
This information is provided by RNS
The company news service from the London Stock Exchange
END
ROMUWSARBBAUUAA
(END) Dow Jones Newswires
December 28, 2017 06:49 ET (11:49 GMT)
Evgen Pharma (LSE:EVG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Evgen Pharma (LSE:EVG)
Historical Stock Chart
From Apr 2023 to Apr 2024